Peter Ghoroghchian, Ceptur CEO

A new start­up wants to take an­ti­sense and siR­NA one step fur­ther, and build more po­tent drugs than Io­n­is and Al­ny­lam

Drug­ging RNA has be­come a hot bio­phar­ma top­ic in re­cent years, par­tic­u­lar­ly af­ter the mas­sive suc­cess­es of the Covid-19 vac­cines. But one biotech is aim­ing to take things a step fur­ther, uti­liz­ing the sin­gle-strand­ed mol­e­cules be­fore they even be­come RNA.

Cep­tur Ther­a­peu­tics launched Wednes­day morn­ing with a $75 mil­lion Se­ries A, the com­pa­ny an­nounced. The goal is to push for­ward a slate of oligonu­cleotide-based ther­a­pies that can con­trol gene ex­pres­sion, and even si­lence some tar­get­ed genes, at the “pre-mR­NA lev­el,” co-founder and CEO Pe­ter Ghoroghchi­an told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.